![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Ullevaal University Hospital |
---|---|
Information provided by: | Ullevaal University Hospital |
ClinicalTrials.gov Identifier: | NCT00290095 |
The purpose of this study is to determine Clinically important difference and Response shift in quality of life in patients with Multiple Myeloma.
Condition |
---|
Multiple Myeloma Quality of Life |
Study Type: | Observational |
Study Design: | Longitudinal, Defined Population, Prospective Study |
Official Title: | Quality of Life in Patients With Multiple Myeloma |
Estimated Enrollment: | 210 |
Study Start Date: | January 2006 |
Estimated Study Completion Date: | January 2008 |
Multiple myeloma is a plasma cell tumor with an annual incidence of 6 pr. 100 000. In the absence of curative treatment, the aim of the therapy is not only to induce an objective response and a prolongation of survival but also to improve the patients quality of life.
This project will raise two problems which make QoL-data hard to interpret
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ann Kristin Kvam, MD | +47 41 92 72 52 | annkristin.kvam@ulleval.no |
Contact: Finn Wisløff, MD, PhD | +47 22 11 92 45 | f.g.b.wisloff@medisin.uio.no |
Norway | |
Ullevaal University Hospital | Recruiting |
Oslo, Norway, 0407 | |
Contact: Ann Kristin Kvam, MD +47 41 92 72 52 annkristin.kvam@ulleval.no | |
Contact: Finn Wisløff, MD, PhD +47 22 11 92 45 f.g.b.wisloff@medisin.uio.no | |
Principal Investigator: Finn Wisløff, MD, PhD |
Principal Investigator: | Finn Wisløff, MD, PhD | Ullevål University Hospital, Norway |
Study ID Numbers: | 1.2005.1269 |
Study First Received: | February 9, 2006 |
Last Updated: | October 16, 2006 |
ClinicalTrials.gov Identifier: | NCT00290095 |
Health Authority: | Norway: The National Committees for Research Ethics in Norway |
Multiple Myeloma Quality of Life Response Shift Clinically Important Difference |
Immunoproliferative Disorders Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Vascular Diseases Quality of Life Paraproteinemias |
Hemostatic Disorders Multiple Myeloma Hemorrhagic Disorders Multiple myeloma Lymphoproliferative Disorders Neoplasms, Plasma Cell |
Neoplasms Neoplasms by Histologic Type Immune System Diseases Cardiovascular Diseases |